Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on October 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 2026 preliminary results include $216 million acquired IPR&D and milestones expense, reducing GAAP and adjusted EPS by $0.11.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 preliminary results include $216 million acquired IPR&D and milestones expense, reducing GAAP and adjusted EPS by $0.11
- Q3 2026 adjusted EPS guidance, including the expense, set at $3.73-$3.77
- Full-year 2026 adjusted EPS guidance, including the expense, set at $13.76-$13.96
- Results remain subject to financial statement closing procedures, creating potential estimate variability
- Expense reflects acquisition and licensing activity, signaling continued investment in AbbVie’s pipeline and external innovation
Item EX-99.1 · Exhibit EX-99.1
- Q3 acquired IPR&D and milestone expense: $216 million, reducing adjusted diluted EPS guidance by $0.11
- Q3 adjusted diluted EPS guidance: $3.73 to $3.77 including the expense
- Full-year 2026 adjusted diluted EPS guidance: $13.76 to $13.96, including $1.251 billion of acquired IPR&D and milestone expense
- Guidance excludes potential acquired IPR&D and milestone expenses after Q3 2026, creating additional downside uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.